Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Oktober 2019 17:02 ET | Quelle: Galera Therapeutics, Inc.

Galera Therapeutics Appoints Christopher Degnan as Chief Financial Officer

MALVERN, Penn., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary...
08. Oktober 2019 08:00 ET | Quelle: Galera Therapeutics, Inc.

Galera Therapeutics Announces Two-Year Tumor Outcomes Data for GC4419

MALVERN, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary...
21. März 2019 10:07 ET | Quelle: Galera Therapeutics, Inc.

Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of Avasopasem Manganese at 2019 NCCN Annual Conference

MALVERN, Pa., March 21, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
23. Oktober 2018 17:45 ET | Quelle: Galera Therapeutics, Inc.

Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting

MALVERN, Penn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
16. Oktober 2018 07:30 ET | Quelle: Galera Therapeutics, Inc.

Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)

Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application MALVERN, Pa., Oct. 16, 2018 ...
19. September 2018 07:30 ET | Quelle: Galera Therapeutics, Inc.

Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication

MALVERN, Pa., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
20. August 2018 07:30 ET | Quelle: Galera Therapeutics, Inc.

Galera Therapeutics Presents Structure and Synthesis of GC4419 at American Chemical Society Annual Meeting

Presentation selected as part of The Halpern Legacy Symposium and press program Phase 3 trial of GC4419 for treatment of severe oral mucositis in patients with head and neck cancer expected to...
29. Juni 2018 08:10 ET | Quelle: Galera Therapeutics, Inc.

Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual Meeting

GC4419 demonstrated clinically significant reduction in duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer Trial investigator Dr. Carryn Anderson honored with...
12. Juni 2018 08:00 ET | Quelle: Galera Therapeutics, Inc.

Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at MASCC/ISOO 2018 Annual Meeting

MALVERN, Penn., June 12, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
03. Juni 2018 11:00 ET | Quelle: Galera Therapeutics, Inc.

Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419 Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

GC4419 met primary endpoint, achieving 92 percent reduction in duration of severe oral mucositis (SOM) in patients with head and neck cancer GC4419 also demonstrated reduction in SOM incidence and...

Nächste Seite